Peptide Comparison
Compare any two peptides side-by-side. Mechanism, FDA status, cost, side effects, and research quality.
Popular
Semaglutide
GLP-1 Weight Loss
Tirzepatide
GLP-1 Weight Loss
Category
GLP-1 Weight Loss
GLP-1 Weight Loss
Also known as
Ozempic, Wegovy, Rybelsus
Mounjaro, Zepbound
FDA Status
FDA-Approved
FDA-Approved
How it works
GLP-1 receptor agonist. Reduces appetite via brain receptors, slows gastric emptying, enhances insulin secretion.
Dual GIP/GLP-1 receptor agonist. Two mechanisms for appetite suppression, insulin sensitivity, and enhanced metabolic effects.
Primary uses
- Weight management
- Type 2 diabetes
- Cardiovascular risk reduction
- Weight management
- Type 2 diabetes
- Obstructive sleep apnea
Dose range
0.25–2.4 mg/week
2.5–15 mg/week
Frequency
Once weekly injection
Once weekly injection
Onset of effects
Appetite reduction within 1-2 weeks; significant weight loss by month 2-3
Appetite reduction within 1-2 weeks; significant weight loss by month 2-3
Common side effects
- Nausea (44%)
- Diarrhea (30%)
- Vomiting (25%)
- Constipation (24%)
- Nausea (33%)
- Diarrhea (23%)
- Vomiting (12%)
- Constipation (18%)
Monthly cost
$199–$499 (self-pay) or $25 with savings card
$299–$499 (self-pay) or $25 with savings card
Research quality
Strong
Strong
Key advantage
Most studied GLP-1 with largest safety database. Oral option available (Rybelsus). Proven cardiovascular benefit (SELECT trial).
Greater weight loss than semaglutide (22.5% vs 14.9% in head-to-head). Dual mechanism. Uniform dose increments easier on GI.
Disclaimer: This comparison is for educational purposes only. Peptide selection should be based on individual medical history, goals, and provider guidance — not a side-by-side chart. Always consult a licensed healthcare provider.
Not sure which one's right for you?
A comparison chart is a starting point. A vetted provider will evaluate your specific situation and recommend what actually makes sense.
Find My Provider